The striking positive correlation between DNMT1 expression and DAC sensitivity across diverse cancer cell lines suggest that the pro-DAC role of DNMT1 is not cell-type specific and underscore the potential of DNMT1 expression as a valuable biomarker to predict patient response to DAC therapy (Fig. 3E). This evidence concerns the gene DNMT1 and cancer.